Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Low-dose sulfonylureas (SUs) enhance the incretin effect and glucose sensitivity.
• Understanding potential synergistic effects with other glucose-lowering agents is crucial for type 2 diabetes management.

Purpose of the Study:

• To evaluate the synergistic efficacy of combining a low-dose sulfonylurea (SU) with a dipeptidyl peptidase 4 (DPP4) inhibitor.
• To assess the impact on beta-cell glucose sensitivity and glucose control in individuals with type 2 diabetes mellitus (T2DM).

Main Methods:

• A randomized crossover study involving 30 T2DM participants.
• Interventions included control, low-dose gliclazide (SU), sitagliptin (DPP4 inhibitor), and their combination (SUDPP4i).
• Mixed meal tests and continuous glucose monitoring were used to assess beta-cell function and glucose levels.

Main Results:

• The combination of SU and DPP4 inhibitor demonstrated an additive glucose-lowering effect (P < .001).
• Beta-cell glucose sensitivity was significantly augmented by the combination therapy (P = .04).
• Additive effects were observed in men, but not women; hypoglycemia risk remained unaffected.

Conclusions:

• Low-dose SU plus DPP4 inhibitor therapy potently lowers glucose by enhancing beta-cell function.
• This combination may offer an effective strategy for T2DM management, potentially mitigating adverse effects of SUs.
• Further double-blind randomized controlled trials are warranted to confirm efficacy and safety.